Silintan Recalls Dietary Supplement Capsules Over Undeclared Meloxicam

Rosemead, CA (January 9, 2026) — The U.S. Food and Drug Administration (FDA) has announced a nationwide recall of Silintan dietary supplement capsules after agency testing found the presence of undeclared meloxicam, a prescription nonsteroidal anti-inflammatory drug (NSAID). According to the FDA, as a result, Anthony Trinh, 123Herbals LLC, marketed the product as a dietary supplement even though it contained an active pharmaceutical ingredient prohibited in supplements, ultimately leading the company to initiate a voluntary recall.

Regulators further explained that the presence of meloxicam classifies Silintan as an unapproved new drug, meaning the product lacks established safety and efficacy data. Additionally, the FDA confirmed the recall applies to all lots within expiry distributed nationwide through the company’s website.

Silintan recall: quick summary

According to the FDA, Anthony Trinh, 123Herbals LLC is voluntarily recalling all Silintan capsules sold online across the U.S. The company markets the product for joint and body ache relief; however, FDA testing found undeclared meloxicam, a prescription NSAID. As regulators noted, consuming meloxicam without medical supervision can pose serious health risks, particularly for older adults and people taking blood thinners or other NSAIDs. So far, the company has not received any reports of adverse events, but regulators urge consumers to stop using the product immediately.

What happened?

According to the agency, Anthony Trinh, 123Herbals LLC initiated the recall after FDA analysis found meloxicam in Silintan capsules. Subsequently, the company announced the recall on January 7, 2026, in coordination with the FDA, and applied it to all lots currently on the market.

In its recall alert, the FDA warned that companies cannot market products containing meloxicam as dietary supplements and stated that exposure above the recommended maximum daily dose of 15 mg may lead to serious, life-threatening events such as blood clots, heart attack, and stroke. Moreover, the agency said the drug may cause gastrointestinal bleeding, kidney injury, and dangerous drug-drug interactions.

Meanwhile, the company sold the product nationwide through its website and packaged it in 25-count plastic bottles with blue labels. At the same time, company officials told regulators they are notifying customers by email and arranging returns.

Affected products

Brand	Product	Size	Best by date	Issue	Affected states
Silintan	Silintan capsules	25-count	All within expiry	Undeclared meloxicam	Nationwide

What caused the issue?

According to the FDA notice, mislabeling and product adulteration triggered the recall because the product contained meloxicam, an approved prescription drug that dietary supplement regulations prohibit. Notably, the agency confirmed that elderly consumers and those taking blood thinners or other NSAIDs face higher risks. In some cases, symptoms may include chest pain, shortness of breath, gastrointestinal bleeding, or kidney problems. To date, no illnesses have been reported.

Questions you might have

Here’s what you should do

• Stop using Silintan capsules immediately
• Check the label for the Silintan name and 25-count blue-label bottle
• Return the product to the place of purchase or discard it safely
• Contact the company at [email protected] or 1-626-656-3202 for refunds
• Consult a healthcare provider if you’ve experienced symptoms

Behind the brand

Anthony Trinh, 123Herbals LLC, sells herbal and dietary supplements online. In its recall notice, the company stated that it has ceased distribution of the affected product and is cooperating with the FDA. Source86 reached out to the company for additional comment, but has not yet received a response.

Other relevant recalls

Similar FDA recalls involving undeclared pharmaceutical ingredients in dietary supplements have affected products marketed for pain relief and sexual enhancement in recent years. Previous Source86 coverage has documented recalls tied to hidden NSAIDs and anabolic steroids, highlighting ongoing enforcement and oversight challenges in the supplement category. More recently, Modern Warrior recalled its Modern Warrior Ready dietary supplement after discovering undeclared drug ingredients.

In recent months, regulators have also taken action on other supplement-related safety concerns. These include Purity Products’ recall of its MyBladder dietary supplement due to potential E. coli contamination, as well as an FDA warning after investigators identified toxic Yellow Oleander in certain weight-loss supplements sold to U.S. consumers. Together, these cases underscore persistent risks tied to inadequate testing, mislabeling, and adulteration in the dietary supplement market.

“Active pharmaceuticals continue to be identified in dietary supplements, especially those marketed for sexual enhancement or weight loss, even after FDA warnings,” the authors of a JAMA Network Open study wrote, noting that hidden drugs in supplements “have the potential to cause serious adverse health effects owing to accidental misuse, overuse, or interaction with other medications”.

Eran Mizrahi, CEO of Source86, said that while this recall involves a single product:

“It underscores a broader truth in the food and supplement industry: safety isn’t optional. Transparency and supplier accountability are essential to maintaining consumer trust.”

Ensuring safe eats

This recall highlights the risks posed by improperly regulated supplements and the importance of strong oversight. Consumers should remain cautious with products promising drug-like effects, and companies must strengthen quality controls to prevent adulteration.

At Source86, we help brands manage ingredient sourcing, FSQA oversight, and private label production with transparency and precision, ensuring supply chains can respond quickly when issues arise. Contact us.